• US health officials are preparing to formally attribute two dozen pediatric deaths to COVID-19 vaccines, according to a new report.
  • The move follows an extensive review of adverse event data and would mark a significant shift in the official safety profile of the mRNA shots.
  • The FDA recently expanded myocarditis and pericarditis warnings for the vaccines, particularly for males aged 12–24.

US health officials are preparing to formally link two dozen pediatric deaths to COVID-19 vaccines, a significant development in the ongoing assessment of the shots' safety profile, according to a new report. The move, if confirmed, would represent one of the most consequential safety determinations since the vaccines were first authorized.

The reported plan centers on approximately 25 child deaths that investigators have concluded were directly caused by complications from COVID-19 vaccination. This determination follows months of intensive review of data from the Vaccine Adverse Event Reporting System (VAERS) and other surveillance networks. People familiar with the matter said the formal attribution process is nearing completion, though the timing of any public announcement remains unclear.

This development comes shortly after the Food and Drug Administration mandated updated warning labels for both Pfizer-BioNTech's Comirnaty and Moderna's Spikevax vaccines. The agency specifically highlighted the risk of myocarditis and pericarditis, particularly in adolescent and young adult males, with recent data suggesting an incidence rate of approximately 1 in 37,000 in males aged 12–24. The updated labeling followed a multi-institutional retrospective study that examined hundreds of myocarditis cases potentially linked to vaccination.

Regulatory experts note that while adverse events following vaccination are rare relative to the hundreds of millions of doses administered, this potential official attribution of pediatric deaths represents a notable moment in pandemic response. The FDA has been moving toward stricter benefit-risk standards for COVID-19 vaccines, particularly for healthy individuals under 65, and has indicated it may require new randomized controlled trial data for full approval in these populations.

Spokespersons for the FDA and Centers for Disease Control and Prevention declined to comment on the specific report when reached Thursday evening. Representatives for Pfizer and Moderna did not immediately respond to requests for comment. The pharmaceutical companies have consistently maintained that their vaccines demonstrate a favorable benefit-risk profile across populations.

The news comes amid ongoing public debate about vaccine safety, particularly regarding childhood vaccination programs. Health authorities continue to emphasize that for most populations, the overall benefits of COVID-19 vaccination outweigh the risks, especially for those at higher risk of severe COVID-19 disease. However, this reported development may prompt renewed scrutiny of vaccination recommendations for younger, healthier demographics.

Market reaction was muted in after-hours trading, though analysts are watching for potential impact on vaccine manufacturers' future revenue projections. Both companies have gradually been shifting their COVID-19 vaccine businesses toward a more traditional commercial market model rather than government-purchased doses.

Editor's Note: This article has been updated to clarify that the reported number of deaths is approximately 25 and that the formal attribution process is still underway.